Summary
Duchenne muscular dystrophy (DMD) is a severe muscle disorder caused by mutations in the DMD gene, resulting in dystrophin loss. Exon-skipping using antisense oligonucleotides (ASO) is a promising approach that partially restores dystrophin by correcting the frameshift during pre-mRNA splicing. However, a weakness of the current approach is that it is mutation-specific and has poor efficacy. To address these, we aim to develop brogidirsen, a new dual-targeting ASO that targets two sequences in exon 44 of the DMD using phosphorodiamidate morpholino oligomer. Here, we conducted an open-label, dose-escalation, Phase I/II trial to evaluate the safety, pharmacokinetics, and activity of brogidirsen, administered intravenously to six ambulant patients with DMD amenable to exon 44 skipping. The study consisted of a dose-escalation part to determine the optimal doses, followed by extended treatment with 40 mg/kg or 80 mg/kg weekly dose for 24 weeks. There were no serious adverse events related to brogidirsen. The results indicated a dose-dependent increase in dystrophin levels, reaching 10.27% and 15.79% of the normal level in the two cohorts. Motor functional tests suggested a trend toward maintaining or slightly improving motor function. There was a dose-dependent increase in Cmax and AUC0–t. High-throughput proteomic assays revealed that serum proteins such as PADI2, TTN, MYOM2, and MYLPF were observed to reduce, suggesting them as biomarkers for therapeutic effects. Notably, in vitro assays using urine-derived cells from patients with DMD support brogidirsen’s high efficacy in the first-in-human studies. These promising results warrant a subsequent multinational trial for DMD.
Competing Interest Statement
H.K. received consulting fees from Nippon Shinyaku for work related to this study and from Biogen, Novartis, Sanofi, Sarepta, Chugai, Daiichi Sankyo, Kaneka, and Astellas for work unrelated to this study. H.K. received grant funding from Nippon Shinyaku for work related to this study and from Sanofi, Chugai, PTC Therapeutics, Taiho, and Pfizer for work unrelated to this study. E.T. received grant funding from Nippon Shinyaku for work related to this study and from Daiichi Sankyo, Taiho, and Takeda for work unrelated to this study. Y.A. received grant funding from Nippon Shinyaku for work associated with this study and from Shionogi, Takeda, and Kaneka for work unrelated to this study. K.K., T.I., Y.S-M., A.I., M.S., C.Y., S.M., and E.H. have no competing interests to declare.
Clinical Trial
NCT04129294
Clinical Protocols
https://onlinelibrary.wiley.com/doi/10.1002/npr2.12335
Funding Statement
grants from the Japan Agency for Medical Research and Development (AMED), Japan awarded to Y.A. (18lm0203066h0001, 21lm0203086h0003),
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complied with the ethical principles of the Declaration of Helsinki and all applicable Japanese local and national regulatory laws. The study protocol and related documentation were approved by the Institutional Review Board of the National Center of Neurology and Psychiatry, Tokyo, Japan (approval number II-012). The study was registered at clinicaltrials.gov (NCT04129294) and the University Hospital Medical Information Network (UMIN000038505).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† These authors shared the first authorship.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
